Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria

Trial Profile

Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Urticaria
  • Focus Pharmacodynamics
  • Most Recent Events

    • 18 Jun 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 20 May 2015 Planned End Date changed from 1 Apr 2015 to 1 Apr 2017 as per ClinicalTrials.gov record.
    • 20 May 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Apr 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top